<DOC>
	<DOC>NCT01523704</DOC>
	<brief_summary>The number of patients with implantable pulse generator (IPG) has steadily increased in Japan causing increment in number of in office follow-ups and greater burden on many hospitals. The purpose of this multicenter randomized study is to demonstrate that BIOTRONIK Home Monitoring system reduces office follow-up visits without compromising patient safety. Patients will be randomized into HM follow-up only (Group 1) or HM &amp; in-office follow-up (Group 2) and will be followed-up for 27 months.</brief_summary>
	<brief_title>Safety and Efficacy Study of IPG Patient With Home Monitoring</brief_title>
	<detailed_description />
	<mesh_term>Bradycardia</mesh_term>
	<criteria>Indicated for IPG implantation under Japanese guidelines Implanted within the last 45 days or being considered for implant with a BIOTRONIK IPG with Home Monitoring Able to utilize HM system throughout the study Ability to give informed consent Geographically stable and able to return for followups for 27 months Over 20 years old Patient able to understand and follow the procedure stated in protocol Contraindicated for IPG under Japanese guidelines Patients who are currently included in another cardiac clinical study Patients with expected life period of less than two years Patients who might undergo heart transplantation in next two years.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>